Polymeric nano-system for macrophage reprogramming and intracellular MRSA eradication

Yun-Jian Yu1, Jian-Hua Yan1, Qi-Wen Chen1

  • 1Key Laboratory of Biomedical Polymers of Ministry of Education, Department of Chemistry, Wuhan University, Wuhan 430072, PR China.

Insights

This study introduces a novel nanocarrier system that targets intracellular Methicillin-Resistant Staphylococcus aureus (MRSA). The system reprograms infected macrophages and utilizes drug release to eradicate MRSA, offering a new approach for persistent infections.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Infectious Diseases

Background:

  • Intracellular Methicillin-Resistant Staphylococcus aureus (MRSA) infections are difficult to treat with conventional antibiotics.
  • Existing therapies struggle to effectively target and eliminate MRSA residing within host cells.

Purpose of the Study:

  • To develop a novel polymeric nano-system for targeted intracellular drug delivery.
  • To reprogram infected macrophages and eradicate intracellular MRSA.
  • To overcome challenges in treating refractory and recurrent MRSA infections.

Main Methods:

  • Formulation of a ferrocene-decorated polymeric nanovesicle (PFMMA-b-PMPC) co-encapsulating clofazimine (CFZ) and interferon-γ (IFN-γ).
  • Utilizing PMPC motifs for specific macrophage internalization and intracellular accumulation.
  • Designing a stimulus-responsive system activated by intracellular hydrogen peroxide for drug release and endosomal escape.

Main Results:

  • The nano-system demonstrated efficient intracellular drug delivery and macrophage reprogramming (M2 to M1 phenotype).
  • Ferrocene-mediated Fenton reaction and CFZ enhanced hydroxyl radical generation for MRSA killing.
  • Achieved robust eradication of intracellular MRSA and antibiotic-tolerant persisters.

Conclusions:

  • The developed nano-system effectively targets intracellular MRSA through immune modulation and reactive oxygen species generation.
  • This approach offers a promising strategy for controlling intracellular MRSA infections.
  • Provides a novel therapeutic avenue for refractory and recurrent MRSA infections.